利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.03 秒)

    Treatment with omega-3 fatty acids and products thereof
    1.
    发明申请
    Treatment with omega-3 fatty acids and products thereof 审中-公开
    用ω-3脂肪酸及其产品处理

    公开(公告)号：US20070104779A1

    公开(公告)日：2007-05-10

    申请号：US11267581

    申请日：2005-11-07

    申请人： Roelof Rongen ,  Robert Shalwitz

    发明人： Roelof Rongen ,  Robert Shalwitz

    IPC分类号： A61K9/64 ,  A61K31/22 ,  A61K31/202

    CPC分类号： A61K31/22 ,  A61K31/202

    摘要： A method for reducing non-HDL cholesterol levels of a subject comprising administering a pharmaceutical composition comprising omega-3 fatty acids to the subject in an amount sufficient to reduce non-HDL cholesterol. The method may include a reduction of the triglyceride levels of the subject and, optionally, an increase in the HDL cholesterol levels of the subject. These methods can be used concurrently with hypertriglyceridemia therapy prescribed by a doctor.

    摘要翻译： 一种用于降低受试者的非HDL胆固醇水平的方法，其包括以足以降低非HDL胆固醇的量向所述受试者施用包含ω-3脂肪酸的药物组合物。 该方法可以包括减少受试者的甘油三酯水平，以及任选地降低受试者的HDL胆固醇水平。 这些方法可以与医生规定的高甘油三酯血症治疗同时使用。

    Treatment of fatty liver
    2.
    发明申请
    Treatment of fatty liver 审中-公开
    脂肪肝的治疗

    公开(公告)号：US20070265340A1

    公开(公告)日：2007-11-15

    申请号：US11649881

    申请日：2007-01-05

    申请人： Robert Shalwitz ,  Roelof Rongen ,  Ihor Terleckyj

    发明人： Robert Shalwitz ,  Roelof Rongen ,  Ihor Terleckyj

    IPC分类号： A61K31/202 ,  A61P1/16

    CPC分类号： A61K31/202

    摘要： Methods and compositions comprising peroxisomal and/or mitochondrial beta oxidation stimulating agents to reverse or resolve, slow the progression of, treat or prevent the development of fatty liver and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure. An active agent that by itself is associated with an increased risk of fatty liver development and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure, may be administered in combination with peroxisomal and/or mitochondrial beta oxidation stimulating agents. A combination regimen involving such agents, as simultaneous or concomitant therapy, or as a fixed dosage form, is also provided.

    摘要翻译： 包括过氧化物酶体和/或线粒体β氧化刺激剂逆转或解决，缓慢进展，治疗或预防脂肪肝的发展和源于脂肪肝的疾病（例如NASH，肝脏炎症，肝硬化和肝衰竭）的方法和组合物。 与脂肪肝发展风险增加相关的活性成分和脂肪肝（如NASH，肝脏炎症，肝硬化和肝衰竭）引起的病症可能与过氧化物酶体和/或线粒体β氧化刺激剂联合使用 。 还提供了涉及这种药物的联合方案，如同时或伴随治疗，或作为固定剂型。

    Treatment with omega-3 fatty acids and PPAR agonist and/or antagonist and a combination product thereof
    4.
    发明申请
    Treatment with omega-3 fatty acids and PPAR agonist and/or antagonist and a combination product thereof 审中-公开
    用ω-3脂肪酸和PPAR激动剂和/或拮抗剂及其组合产物治疗

    公开(公告)号：US20060211749A1

    公开(公告)日：2006-09-21

    申请号：US11293513

    申请日：2005-12-05

    申请人： George Bobotas ,  Robert Shalwitz ,  Roelof Rongen

    发明人： George Bobotas ,  Robert Shalwitz ,  Roelof Rongen

    IPC分类号： A61K31/426 ,  A61K31/22 ,  A61K31/202 ,  A61K31/192

    CPC分类号： A61K31/426 ,  A61K31/192 ,  A61K31/202 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

    摘要： A method and composition for blood lipid therapy that comprises administering to the subject an effective amount of a PPAR agonist and/or antagonist and an omega-3 fatty acid. The methods and compositions include combination products or concomitant therapy for the treatment of subjects with hypertriglyceridemia, hypercholesteremia, mixed dyslipidemia, vascular disease, artherosclerotic disease and related conditions, obesity, the prevention or reduction of cardiovascular and vascular events, the reduction of insulin resistance, fasting glucose levels and postprandial glucose levels, and/or the reduction of incidence and/or the delay of onset of diabetes.

    摘要翻译： 一种用于血脂治疗的方法和组合物，其包括向受试者施用有效量的PPAR激动剂和/或拮抗剂和ω-3脂肪酸。 所述方法和组合物包括用于治疗患有高甘油三酯血症，高胆固醇血症，混合性血脂异常，血管疾病，动脉粥样硬化疾病和相关病症，肥胖症，预防或减少心血管和血管事件，降低胰岛素抵抗的组合产品或伴随治疗， 空腹血糖水平和餐后葡萄糖水平，和/或糖尿病发病率和/或延迟发作的降低。

    Treatment of mucositis
    8.
    发明申请
    Treatment of mucositis 审中-公开

    公开(公告)号：US20060105985A1

    公开(公告)日：2006-05-18

    申请号：US11318677

    申请日：2005-12-27

    申请人： Robert Shalwitz ,  Tapas Das ,  Paul Johns ,  James Leach

    发明人： Robert Shalwitz ,  Tapas Das ,  Paul Johns ,  James Leach

    IPC分类号： A61K31/7076 ,  A61K31/7072

    CPC分类号： A61K9/0095 ,  A61K9/0056 ,  A61K9/2059 ,  A61K9/4866 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708

    摘要： Disclosed are compositions and methods for alleviating mucositis, wherein said methods and compositions are directed to the formulation or use of selected nucleoside derivatives, especially ADP-ribose, that conform to the general formula A-B-X and pharmaceutically acceptable salts thereof, wherein “A” is a nucleoside structure selected from adenosine, guanosine, and uridine; “B” is a diphosphate linkage attached to the 5′ carbon of the nucleoside ribose moiety; and “X” is attached to B an is a moiety selected from hydrogen, furanose, or pyranose. Also disclosed are pharmaceuticals and nutritional liquid embodiments thereof, including lozenges, mouthwashes, or other product forms that effectively coat the oral, laryngeal or other mucosal areas. It has been found that these compositions and methods effectively alleviate mucositis in susceptible individuals, especially when administered prior to, during, or after treatments commonly associated with the development of mucositis such as certain chemotherapies, radiation therapies, or combinations thereof.

    COMPOUNDS AND COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER
    10.
    发明申请
    COMPOUNDS AND COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER 有权
    用于稳定HYPOXIA可诱导因子-2 ALPHA的化合物和组合物作为治疗癌症的方法

    公开(公告)号：US20120316204A1

    公开(公告)日：2012-12-13

    申请号：US13489400

    申请日：2012-06-05

    申请人： Robert Shalwitz ,  Joseph H. Gardner

    发明人： Robert Shalwitz ,  Joseph H. Gardner

    IPC分类号： A61K31/4418 ,  A61P35/00 ,  C07D213/81

    CPC分类号： A61K31/4418 ,  C07D213/81

    摘要： Disclosed herein is {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and the ester and amide prodrugs thereof, that can stabilize hypoxia inducible factor-2 alpha (HIF-2α) and thereby provide a method for treating cancer. Further disclosed are compositions which comprise {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and/or a prodrug thereof which can be used to treat cancer.

    摘要翻译： 本文公开了可以稳定缺氧诱导因子-2α（HIF-2α）的{[5-（3-氟苯基）-3-羟基吡啶-2-羰基] - 氨基}乙酸及其酯和酰胺前药， 提供治疗癌症的方法。 进一步公开的是包含可用于治疗癌症的{[5-（3-氟苯基）-3-羟基吡啶-2-羰基] - 氨基}乙酸和/或其前药的组合物。